Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
Feature|Articles|June 27, 2025
Biden’s prostate cancer diagnosis underscores importance of screening, awareness
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
Advertisement
Advertisement
Former President Joseph R. Biden’s recent diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer has offered a sobering reminder that prostate cancer remains a growing concern for public health. In the US, incidence rates have been steadily rising since 2014, driven primarily by increases in advanced disease. The American Cancer Society (ACS) estimates that in 2025, more than 313,000 men will be diagnosed with prostate cancer and over 35,000 men will die from the disease.1
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Advertisement
Advertisement